CenterForBiosimilars

In a year-long RA trial, a golimumab biosimilar matched the reference biologic on efficacy & safety,reinforcing confidence in biosimilars while supporting lower costs, better affordability & broader access.💊 Read more: hubs.li/Q047CWnx0 #biosimilars #access #rheumatology

Biosimilars are reshaping access, affordability, and sustainability in biologics. How is your organization feeling the impact of recent policy shifts and FDA draft guidance? Share your perspective in our new poll: hubs.li/Q047wZLw0 💬📊 #biosimilars #access #affordability

In 18 trials, switching from reference etanercept to a biosimilar showed no loss of efficacy or safety—supporting confidence in biosimilars and potential gains in affordability & access. 💊 Read more: hubs.li/Q0478GK-0 #biosimilars #biologics #affordability #rheumatology

Major knowledge gaps remain in biosimilar insulin switching. HCPs express safety and device concerns; patients weigh brand trust and cost. Strong evidence is essential for confident transitions. 🧬 hubs.li/Q046Jz080 #biosimilars #biologics #diabetes #drugcosts

The global biosimilar market is reshaping: Sandoz restructures around a “golden decade,” Celltrion dominates key Asian markets, while US regulatory paths remain complex. Big implications for costs, competition & access to biologics. 🧬🌏 hubs.li/Q046Jhl80 #biosimilars

FDA’s new draft guidance could cut biosimilar PK study costs by up to 50%, aiming to ease development expenses and boost competition in biologics. That’s a critical step toward better affordability and access—but structural barriers remain. 🧬 hubs.li/Q0469S-z0 #biosimilars

Clinician confidence in ophthalmology biosimilars across Europe remains low—despite strong evidence on safety, efficacy & cost savings. Patients risk missing out on affordable care and better access. 🧬🌍 hubs.li/Q0465Dz_0 #biosimilars #biologics #patientaccess

Our latest newsletter is live. We explore how biosimilars are expanding treatment options while US legal hurdles, biologics patent protections, and rising costs shape affordability and access. Catch up and subscribe. hubs.li/Q046033J0 #biosimilars #biologics #affordability

Don’t miss it: our newsletter goes live today at 4 PM ⏰ We’re breaking down how biosimilars are changing access, affordability, and biologics costs—and what it means for health innovations and patient care. Tune in and subscribe. #biosimilars #biologics #healthcare

Just a reminder to keep an eye out for our LinkedIn newsletter dropping tomorrow 👀📰 Trusted, evidence-informed insights for healthcare professionals—quick to scan, easy to apply. Click below to get notified. 🩺 hubs.li/Q045J-jG0 #Healthcare #ValueBasedCare

Biosimilars continue to reshape oncology markets. New data from The Center for Biosimilars on a biosimilar-backed triplet regimen in heavily pretreated liver cancer highlight signals for payers, health systems, and manufacturers. 📊 Read more: hubs.li/Q045mNlS0 #biosimilars

New from The Center for Biosimilars: a biosimilar-backed triplet regimen shows feasibility in heavily pretreated liver cancer, with implications for sustainability and access. 🧬💊 Read the article: hubs.li/Q0458tGP0 #biosimilars #livercancer #oncology #valuebasedcare

Your feedback is driving our next focus at The Center for Biosimilars: deeper dives on costs, payer trends, outcomes, access, and FDA updates. Stay tuned and watch our bio for new features. 🌐🤝 #biosimilars #healthcarepolicy

Omalizumab biosimilars show how competition can expand patient access and reduce costs in allergic and respiratory care. Early data link biosimilar entry to lower spending and greater affordability across systems. 🌍💊📊 hubs.li/Q044QKd-0 #Biosimilars #HealthcareCosts

Biosimilars are transforming US healthcare with $56B in savings, driving access, affordability, and market stability. 💊 See new Cardinal Health data on their impact in specialty care: hubs.li/Q044rXll0

What topics on biosimilars matter most to you right now—access, costs, FDA approvals, or biologics and affordability? Share your perspective in our new poll so we can tailor our coverage to your needs. 🌐 Take the poll here: hubs.li/Q044rHxt0 #biosimilars #biologics #access

Breakthrough: Biosimilar trastuzumab emtansine delivers consistent PFS in HER2+ breast cancer, paving the way for greater access and affordability in oncology as biosimilars reshape the future of care. hubs.li/Q0440wQ10 #biosimilars #access #affordability

Filkri, a short-acting filgrastim biosimilar for neutropenia, raises key questions about access, affordability, and biologics costs in oncology care. How do you think its approval will impact care? Vote in our poll and read the full analysis: hubs.ly/Q043-JQz0 #Biosimilars

Filkri, Accord Biopharma’s new short-acting filgrastim biosimilar, is reshaping oncology by expanding access and affordability. Explore its impact on pricing, payer strategies, and patient outcomes. hubs.li/Q043NY990 #Biosimilars #Access #Affordability

Biosimilars are transforming specialty care by driving new standards in access, affordability, and sustainability. 📊 Discover the latest market trends shaping pricing and payer strategies here: hubs.li/Q043zN7n0 #Biosimilars #Affordability #Access